SOPH Chief Medical Officer Philippe Menu Sells $28K of Stock

Philippe Menu, the Chief Medical Officer of SOPHiA GENETICS SA (NASDAQ: SOPH), sold 5,000 shares of the company on June 25, 2026. The transaction was valued at $27,500 and was carried out under a Rule 10b5-1 trading plan. This type of plan lets company insiders schedule trades in advance to avoid any concerns about using private information.

Details of the Transaction

Menu sold the shares at a price of $5.50 each. This isn't the first time the Chief Medical Officer has trimmed his holdings recently; he also sold 5,000 shares on June 12, 2026, for about $24,750. These trades are part of a broader pattern of executive activity at the Swiss-based technology firm, which has seen several leaders move shares in the same month.

Activity Among Company Leaders

Other executives have also been active in the market. On the same day as Menu's most recent sale, Chief Technology Officer Abhimanyu Verma sold 6,944 shares for $38,261.44. CEO Jurgi Camblong has also been active, selling a small block of shares on June 25 before executing a larger transaction on June 26. On that day, Camblong bought 31,940 shares at $3.16 each, a transaction worth over $100,000, shortly after a separate sale of the same number of shares.

SOPHiA GENETICS Stock Performance

On Saturday, SOPHiA GENETICS shares were valued at $5.75. The stock has been trading in a wide range over the past year, hitting a low of $3.37 and a high of $8.98. The current price is sitting just above the 200-day moving average of $5.55, which is a level often watched to determine long-term trends. With a market value of roughly $691.3 million, the company remains a mid-sized player in the health information services sector.

Recent Financial Results

In its latest financial reports, SOPHiA GENETICS posted revenue of $86.17 million. The company saw its revenue grow by 27.2% compared to the previous period. However, like many growing tech firms in the healthcare space, it isn't profitable yet. The company reported a net margin of -93.8% and a return on equity of -1.01. The next chance for investors to see if the company is closing the gap toward profitability will be the earnings announcement scheduled for November 3, 2026.

Analysts Set New Price Targets

Investment firms have maintained a positive outlook on the stock. On October 12, 2026, HC Wainwright & Co. reiterated a Buy rating with a $14.00 price target. This followed their earlier moves in August and July where they consistently labeled the stock a Buy. BTIG also kept its Buy rating in August, setting a target of $9.00. Across four different analysts, the average price target stands at $9.75, suggests there could be significant room for the stock to grow if it meets expectations.

About SOPHiA GENETICS

SOPHiA GENETICS is a Swiss company that runs a cloud-based software platform used by hospitals and labs to analyze complex medical data. Their technology helps doctors and researchers find insights in large data sets to improve patient care, particularly in cancer research. They work with major partners like AstraZeneca to develop diagnostic tools that help match patients with the right oncology treatments.

What's Ahead for SOPHiA GENETICS SA

Investors will likely watch the November earnings report to see if the company's 27.2% revenue growth continues to scale. While insider sales can sometimes draw attention, the planned nature of these trades and the CEO's recent purchase suggest a mix of activity rather than a single direction. It is worth noting that 13F filings and insider reports show past actions and might not show what these investors hold today.